After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...
Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback